What is the official website of Cooper Pharma ?

The official website of Cooper Pharma is http://cooperpharma.ma.

What is Cooper Pharma's cybersecurity risk score?

Cooper Pharma has an AI-generated cybersecurity risk score of 760 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Cooper Pharma experienced?

According to Rankiteo, Cooper Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Cooper Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, Cooper Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Cooper Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, Cooper Pharma is not certified under SOC 2 Type 1.

Does Cooper Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, Cooper Pharma does not hold a SOC 2 Type 2 certification.

Does Cooper Pharma comply with GDPR ?

According to Rankiteo, Cooper Pharma is not listed as GDPR compliant.

Does Cooper Pharma have PCI DSS certification ?

According to Rankiteo, Cooper Pharma does not currently maintain PCI DSS compliance.

Does Cooper Pharma comply with HIPAA ?

According to Rankiteo, Cooper Pharma is not compliant with HIPAA regulations.

Does Cooper Pharma have ISO 27001 certification ?

According to Rankiteo,Cooper Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Cooper Pharma operate in ?

Cooper Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Cooper Pharma have ?

Cooper Pharma employs approximately 892 people worldwide.

Does Cooper Pharma own any subsidiaries ?

Cooper Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does Cooper Pharma have ?

Cooper Pharma's official LinkedIn profile has approximately 111,630 followers.

What is the NAICS classification code for Cooper Pharma ?

Cooper Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Cooper Pharma have a Crunchbase profile ?

No, Cooper Pharma does not have a profile on Crunchbase.

Does Cooper Pharma have a LinkedIn profile ?

Yes, Cooper Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/cooper-pharma.

How many cybersecurity incidents has Cooper Pharma experienced ?

As of July 17, 2026, Rankiteo reports that Cooper Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does Cooper Pharma have ?

Cooper Pharma has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Cooper Pharma

Boost Score +25 with badge (5 left)

760

/1000

Fair

785

/1000

Fair

Cooper Pharma Vendor Cyber Rating & Cyber Score

cooperpharma.ma

Add Your Compliance Badge

Depuis 1933, Cooper Pharma, laboratoire pharmaceutique marocain, accompagne les professionnels de la santé, au service d’une mission : accroitre l’accessibilité de tous aux médicaments. Cooper Pharma est aujourd’hui le laboratoire leader de l’industrie pharmaceutique nationale, avec sa gamme de produits propres, couvrant avec plus d’une centaine de spécialités, les aires thérapeutiques majeures. Aux côtés de cette gamme de génériques de marque, Cooper Pharma est le partenaire d’une vingtaine de multinationales pour lesquelles il représente une centaine de médicaments, sous licence. Avec plus de 1200 collaborateurs, Cooper Pharma incarne un modèle unique au Maroc avec sa triple activité : - Fabriquant : Une unité industrielle de

Cooper Pharma A.I CyberSecurity Scoring

Scoring History

Cooper Pharma

Cooper Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Cooper Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Cooper Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cooper Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Cooper Pharma in 2026.

Incident Types Cooper Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cooper Pharma in 2026.

Incident History - Cooper Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Cooper Pharma Subsidiaries

Parent Company

Cooper Pharma

Pharmaceutical Manufacturing

Website: http://cooperpharma.ma

Company Size: 892

No subsidiary data available for this company.

Loading…

Cooper Pharma Similar Companies

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Loading…

NEWS

Cooper Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 01, 2025 07:00 AM

Cooper Parry swoops for 70-strong cybersecurity firm in deal that adds “even more firepower” to the group

Cooper Parry - the acquisitive accountancy group backed by New York-based Lee Equity - has acquired a 70-strong cybersecurity specialist in...

Read Article

April 24, 2025 07:00 AM

Burgess Cooper joins Adani’s new OT cybersecurity division as CEO

Veteran cybersecurity leader Burgess Cooper has joined Adani Enterprises Limited's newly launched Operational Technology (OT) Cybersecurity...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-44453

SUMMARY

h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 6b5370d, h2o is vulnerable to a Denial of Service attack when calling alloca under certain conditions. When serving static files, h2o builds the file path on stack, by calling alloca. The maximum size of the memory allocated using alloca can be as huge as ~600KB, which exceeds the default pthread stack size used by musl libc (128KB). If the amount of memory allocated by alloca exceeds the stack size, the h2o server crashes with a segmentation fault, while it tries to touch the guard page. This issue has been fixed by commit 6b5370d.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44452

SUMMARY

h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 8dc37cb, when h2o receives a ClientHello message over TLS or QUIC and it contains a zero-length SNI extension, the h2o server runs over the zero-length hostname while trying to copy the hostname, assuming that it is NULL-terminated. This is a potential denial-of-service attack vector in sense that it might trigger segmentation violation. This issue has been fixed by commit 8dc37cb.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-44436

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 8b178e6, Quicly is vulnerable to a Denial of Service attack through connection state corruption. In QUIC Invariants, the maximum length of a Connection ID is 255 bytes, while QUIC version 1 further restricts the maximum to 20 bytes. Quicly implements QUIC version 1 and therefore its CID buffers are limited to 20 bytes. However, to be able to respond to unknown versions of QUIC, its packet decoder accepts Connection IDs of up to 255 bytes. As its CID buffers are merely 20 bytes long, Quicly must reject QUIC version 1 packets with Connection IDs longer than that. The command line tool bundled with Quicly has had that check, however the library itself lacked such enforcement. As a consequence, when used by applications that lack their own enforcement, the connection state becoming inconsistent to buffer overrun. Fortunately, the overflow stops within the allocated chunk of memory, but nevertheless, the bug leads to assertion failures. This issue has been fixed by commit 8b178e6.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44435

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 937d0e9, an assertion failure is raised when the total number of valid handshake messages received over a CRYPTO stream of a single packet number space exceeds 32KB, causing a Denial of Service. This issue has been fixed by commit 937d0e9.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44434

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit dccf5d4, Quicly was vulnerable to stateless reset injection through lack of packet entry validation. The QUIC protocol is designed to withstand packet injection attacks, once the handshake is complete. Only packets that carry some secret patterns are considered as stateless resets. Quicly allows the peer to share up to 4 such patterns per connection. However, until now, it failed to determine which of the 4 slots that it uses to retain the secret patterns contains a valid entry. As the slots are zero-initialized, the failure meant that, unless the peer advertised 4 of such patterns, an all-zero pattern was treated as a stateless reset.In effect, this allowed an on-path attacker to reset QUIC connections governed by Quicly. This issue has been fixed by commit dccf5d4.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…